Background The treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC) has become a dominant field of ongoing translational research. Still, the effect of the first KRAS G12C inhibitor, sotorasib, or next-generation inhibitors, such as fulzerasib, in KRAS-mutant NSCLC patients is short-lived. Although the obje...
A. Giménez-Capitán, D. Olmo-González, E. Martínez-Pérez et al.· Annals of Translational Medi...· 0 citations
INTRODUCTION
The tumor suppressor TP53 is the most frequently mutated gene in human cancer, and drugs targeting specific mutant p53 proteins have been developed. Rezatapopt, which reactivates the Y220C p53 protein, was recently evaluated in the Phase I PYNNACLE trial in patients with solid tumors, with promising result...
M. Molina-Vila, Z. Tsourti, A. Stenzinger et al.· Journal of Thoracic Oncology· 0 citations
Highlights • MET inhibitor resistance is heterogeneous across distinct MET-altered NSCLC.• Spatial transcriptomics reveal shared ECM remodeling in tumors upon progression.• In vitro models partially recapitulate aspects of clinical MET inhibitor resistance.• CRISPR and combination drug screens reveal overlapping functi...
M. Simard, E. Marin, S. García-Román et al.· Neoplasia· 0 citations
Melanoma has one of the highest propensities to metastasize to the brain, and despite major advances with immune checkpoint inhibitors, brain metastases remain a leading cause of morbidity and mortality. The biological mechanisms governing brain colonization, immune evasion, and resistance to therapy are incompletely u...
R. Rosell, M. González-Cao, D. Olmo-Gónzalez et al.· Annals of Translational Medi...· 0 citations
In the H2030 xenograft model, tumor growth was significantly inhibited by treatment with the three-drug combination of omeprazole, sotorasib, and selinexor, with no apparent toxic side-effects or weight loss observed.